|Bid||84.12 x 800|
|Ask||84.22 x 800|
|Day's Range||81.79 - 84.48|
|52 Week Range||41.07 - 90.25|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||95.17|
LONDON, Jun 15, 2021--LivaNova PLC announced it received approval from the U.S. FDA to proceed with its IDE clinical study, OSPREY, for obstructive sleep apnea treatment.
NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. “Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new
LivaNova PLC today announced it has successfully completed the initial closing of the divestiture of its heart valve business to Gyrus Capital.